Jpmorgan Chase & CO Intellia Therapeutics, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NTLA
# of Institutions
321Shares Held
88.6MCall Options Held
673KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$186 Million2.39% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$145 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$138 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$72.7 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$66.1 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.15B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...